Internation No PCT/US2005/006108

A. CLASSI IPC 7	FICATION OF SUBJECT MATTER A61K48/00 A61K38/17 A61P35/0	0				
According to International Patent Classification (IPC) or to both national classification and IPC						
	SEARCHED					
Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N A61K						
Documentat	ion searched other than minimum documentation to the extent that si	uch documents are included in the fields se	earched			
Electronic d	ata base consulted during the International search (name of data bas	se and, where practical, search terms used)			
EPO-Internal, BIOSIS, WPI Data, PAJ, EMBASE						
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT					
Category °	Citation of document, with indication, where appropriate, of the rele	evant passages	Relevant to claim No.			
X	NEMUNAITIS J ET AL: "Adenovirus-		1-30			
	p53 gene transfer in sequence wit cisplatin to tumors of patients w		•			
	non-small-cell lung cancer"					
	JOURNAL OF CLINICAL ONCOLOGY,					
	vol. 18, no. 3, February 2000 (20 pages 609-622, XP002331130	100-02),				
,	ISSN: 0732-183X					
	page 610, left-hand column, parag	raph 5 -				
	right-hand column, paragraph 1 page 611, left-hand column, parag	raph 2	í			
	page 612, right-hand column, para					
:	page 609					
	abstract					
	-	·/				
•		•				
X Further documents are listed in the continuation of box C. Patent family members are listed in annex.						
° Special ca	tegories of cited documents:	*T* later document published after the inte	mational filing date			
'A' docume	ant defining the general state of the art which is not lered to be of particular relevance	or priority date and not in conflict with cited to understand the principle or the	the application but			
"E" earlier o	document but published on or after the international	invention "X" document of particular relevance; the o				
filing date cannot be considered novel or cannot be considered to "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another cannot be considered novel or cannot be considered to Involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention						
citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or document is combined with one or more other such docu-						
other means "P" document published prior to the international filing date but later than the priority date claimed "A" document member of the same patent family						
	actual completion of the international search	& document member of the same patent family Date of mailing of the international search report				
22 June 2005 04/08/2005						
Name and mailing address of the ISA		Authorized officer				
European Patent Office, P.B. 5818 Patentiaan 2 NL – 2280 HV Rijswijk						
	Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Sitch, W				

Internation I Application No PCT/US2005/006108

·	· · · · · · · · · · · · · · · · · · ·	PCT/US200	
C.(Continua	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
X	BULLER RICHARD E ET AL: "Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500" CANCER GENE THERAPY, vol. 9, no. 7, July 2002 (2002-07), pages 567-572, XP002331131 ISSN: 0929-1903	<u>-</u>	1-30
X	page 568, left-hand column, paragraph 1 - page 569, left-hand column, paragraph 1 DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE,		1-35
	PHILADELPHIA, PA, US; 1997, PIROLLO KATHLEEN F ET AL: "P53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy" XP002331134 Database accession no. PREV199799548911 abstract & ONCOGENE, vol. 14, no. 14, 1997, pages 1735-1746, ISSN: 0950-9232		
	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, CHANG ESTHER H ET AL: "Restoration of the G-1 checkpoint and the apoptotic pathway mediated by wild-type p53 sensitizes squamous cell carcinoma of the head and neck to radiotherapy" XP002331135 Database accession no. PREV199799596956 abstract & ARCHIVES OF OTOLARYNGOLOGY HEAD AND NECK SURGERY, vol. 123, no. 5, 1997, pages 507-512, ISSN: 0886-4470		1-35
	-/		
	•		

	PCT/US2005/006108				
	(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
X	GURNANI MAYA ET AL: "Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer" CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 44, no. 2, August 1999 (1999-08), pages 143-151, XP002331132 ISSN: 0344-5704 page 143 abstract page 144, right-hand column, paragraph 1 page 145, right-hand column, paragraph 4 page 147, right-hand column, paragraph 4 page 148, right-hand column, paragraph 1 page 149	1-35			
X	NIELSEN L L ET AL: "ADENOVIRUS-MEDIATED P53 GENE THERAPY AND PACLITAXEL HAVE SYNERGISTIC EFFICACY IN MODELS OF HUMAN HEAD AND NECK, OVARIAN, PROSTATE AND BREAST CANCER" CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 4, no. 4, April 1998 (1998-04), pages 835-846, XP002331133 ISSN: 1078-0432 page 835 abstract page 837, left-hand column, last paragraph - right-hand column, paragraph 1 page 843; figures 6,7	1-35			
X	ALEXANDER W A ET AL: "Tumor-targeted sensitization to chemotherapy by systemically delivered ligand mediated wtp53 gene therapy" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, March 1999 (1999-03), page 596, XP001206623 & 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999 ISSN: 0197-016X abstract #3930	1-35			



Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)				
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:				
Although claims 130 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.				
Claims Nos.: because they relate to parts of the international Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:				
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Fule 6.4(a).				
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)				
This international Searching Authority found multiple inventions in this international application, as follows:				
•				
As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.				
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.				
As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:				
4. No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:				
_				
Remark on Protest The additional search fees were accompanied by the applicant's protest.				
No protest accompanied the payment of additional search fees.				